Home Medix HM-BV-30 vs ResMed Lumis 150 VPAP ST

2 min read By HHZ Editorial Next review

HM-BV-30 is the value winner at roughly ₹38,000 when the prescriber is comfortable with its TVAPS implementation and offline Claro reporting. ResMed Lumis 150 is the premium clinical-workflow winner at roughly ₹63,490 when iVAPS, ResMed algorithms, AirView-compatible follow-up, and the wider ResMed ventilation ecosystem are required.

This is not a simple “same specification, lower price” comparison. HM-BV-30 uses TVAPS terminology; Lumis 150 uses iVAPS. Both sit in the volume-assured bilevel category, but the algorithms are not interchangeable and the clinician must translate the prescription.

FactorHM-BV-30ResMed Lumis 150
Indicative priceAbout ₹38,000About ₹63,490
Published modesCPAP, APAP, S, Auto S, ST, T, TVAPSIncludes S, ST, T and iVAPS-class therapy by SKU
Pressure ceilingUp to 30 cmH₂OConfirm exact Indian SKU
ReportingMemory card + Claro on Windows/macOSResScan/AirView ecosystem by configuration
Best fitValue-focused clinician-supported TVAPSPremium iVAPS and connected clinical workflow

Where HM-BV-30 wins

Value: it delivers a broad mode stack and a 4–30 cmH₂O published pressure range at roughly ₹25,000 less.

Offline clinical detail: Claro provides summaries, trends, waveforms, events, pressure, leak, airflow, and AHI views from the memory card on Windows or macOS. That supports periodic review without locking the patient to a cloud platform.

Warranty positioning: the three-year/10,000-hour published warranty and India-side brand position can be attractive where Home Medix has responsive service.

HM-BV-30 is compelling for a cost-limited home NIV patient whose treating team has reviewed the TVAPS controls and can titrate the device directly.

Where Lumis 150 wins

iVAPS ecosystem: Lumis 150 is the correct choice when the clinician has prescribed or standardised on ResMed iVAPS rather than a generic volume target.

Clinical familiarity and data: ResMed’s ventilation platform, software, accessories, and service documentation are familiar to many sleep and respiratory teams. Connected configurations can simplify remote follow-up.

Premium support footprint: for complex neuromuscular, hypoventilation, or overlap cases, a mature device-specific clinical workflow can justify the higher price.

What must match before switching

Do not map these machines using “target volume” alone. The clinician should verify:

  • IPAP/EPAP range and maximum pressure support.
  • Backup-rate behaviour and timed inspiration controls.
  • How target ventilation or volume is calculated and adjusted.
  • Trigger, cycle, rise-time, leak compensation, and alarm behaviour.
  • Mask type, humidification, supplemental-oxygen connection, and report availability.

Read TVAPS, AVAPS, and iVAPS devices in India before treating the terms as equivalents.

Verdict

HM-BV-30 is the stronger commercial-value choice when its TVAPS mode fits the clinician’s plan and local service is adequate. Lumis 150 is the stronger clinical-platform choice when iVAPS, ResMed’s ecosystem, or connected specialist follow-up is load-bearing. For complex ventilation, the cheapest compatible-looking machine is not necessarily compatible.

Frequently asked questions

Is TVAPS the same as iVAPS?
No. Both are volume-assured bilevel approaches, but their algorithms, targets, controls, and device implementation differ. A prescription should be mapped by a ventilation clinician, not by matching acronyms.
Can HM-BV-30 replace Lumis 150?
Only if the clinician confirms that HM-BV-30's modes, pressure range, backup rate, target-volume controls, alarms, and monitoring meet the patient's prescription.
Which offers better value?
HM-BV-30 offers more modes per rupee. Lumis 150 offers the stronger premium ecosystem and is preferable when the care team already uses ResMed's iVAPS and data workflow.